Latest News

Friday, November 27, 2015 | Conferences

Top News From AAO 2015: Slideshow

Ophthalmologists from around the world gathered in Las Vegas from November 14 to 17 to hear the latest research in their field during the American Academy of Ophthalmology (AAO) 2015 annual meeting.

Read the full story

Friday, November 27, 2015 | Medical Studies

Response to Anti-VEGF in Macular Edema Evident at 3 Months

For patients with diabetic macular edema, long-term response to vascular endothelial growth-factor (VEGF) inhibitors can be predicted after just three injections, according to a post hoc analysis…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

Largest Prospective Study Evaluating the Effect of Vigabatrin on Vision

The largest prospective study evaluating vision changes in adult patients with refractory complex partial seizures (rCPS) will be available to view next month at the annual meeting of the American Epi…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

Prevalence of Laser Vision Correction in Ophthalmologists Who Perform Refractive Surgery

Ophthalmologists who perform LVC were significantly more likely than the general population to have LVC in their own eyes. The prevalence of refractive errors was significantly higher among ophthalmol…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

New Strategies but Modest Benefit in Uveal Melanoma

Uveal melanoma is a rare form of melanoma and is difficult to treat, with low response rates to therapies currently in use. Findings from two small studies that investigated two treatment strategies i…

Read the full story

Wednesday, November 25, 2015 | Medical Studies

Neural Deficit Progresses After Collagen Crosslinking for Keratoconus

Collagen crosslinking (CXL) treatment appears to halt the progression of keratoconus in young patients, but nerve disorientation persists, according to European investigators. Dr. Neil Lagali, who wor…

Read the full story

Tuesday, November 24, 2015 | Conferences, Envision

Envision Raises $322K at Annual Gala

At its eighth annual “Evening with Envision” gala held at the Hyatt Regency Wichita on October 23, Envision raised more than $322,000 in support of its mission to improve the quality of li…

Read the full story

Tuesday, November 24, 2015 | Partnerships, Imprimis Pharmaceuticals

Nvision Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

Imprimis Pharmaceuticals and Nvision Eye Centers, one of the largest US providers of LASIK and cataract surgery, announced they have entered into an agreement to provide Nvision Eye Center patients wi…

Read the full story

Tuesday, November 24, 2015 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for Dextenza for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix announced enrollment of the first patients in a second phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained release dexamethasone), 0.4mg intracanalicul…

Read the full story

Tuesday, November 24, 2015 | Product Releases, Nidek

Nidek Launches Tonoref III Auto Ref/Kerato/Tono/Pachymeter

Nidek has announced the launch of the Tonoref III Auto Ref/Kerato/Tono/Pachymeter, according to a company news release. The Tonoref III combines the functionality of an auto-refractometer, auto-…

Read the full story

Monday, November 23, 2015 | Clinical Trials, Alimera Sciences

Alimera Sciences Announces New 36-Month Analysis That Shows Iluvien Slows Diabetic Retinopathy Progression

Alimera Sciences announced that a new analysis of patients from the FAME Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edem…

Read the full story

Monday, November 23, 2015 | Medical Studies

New Dry Eye Gel Improves Some, but Not All, Symptoms

Treating patients with dry eye syndrome for 4 weeks with carbomer-based lipid-containing artificial tear formulations (CBLAT) on top or instead of their usual artificial tear treatment improved their …

Read the full story

Monday, November 23, 2015 | Acquisitions/Mergers, Allergan

Pfizer and Allergan to Combine in $160 Billion Deal

Pfizer and Allergan announced Monday that the companies entered into a definitive merger agreement to combine in a stock transaction valued at a total enterprise value of about $160 billion, or $363.6…

Read the full story

Friday, November 20, 2015 | Management/Leadership, NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization

NovaBay Pharmaceuticals announced a corporate restructuring to focus on the commercialization of its prescription Avenova Lid and Lash Cleanser. NovaBay is also taking steps to reduce operating expens…

Read the full story

Thursday, November 19, 2015 | Glaucoma

Glaukos Submits IND Application to FDA to Study iDose Travoprost Intraocular Implant in Glaucoma Patients

Glaukos announced that it has submitted an investigational new drug (IND) application to the FDA seeking authorization to study its travoprost intraocular implant with the iDose delivery system for in…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $27.27  0.00% 
 Akorn, Inc. $33.44  0.00% 
 Alimera Sciences, Inc. $3.22  0.00% 
 Allergan $319.76  0.00% 
 Avalanche Biotechnologies $10.10  0.00% 
 Bayer $133.54  0.00% 
 Can-Fite Biopharma $3.23  0.00% 
 Carl Zeiss Meditec $26.71  0.00% 
 Cooper Companies, Inc. $146.96  0.00% 
 Eleven Biotherapeutics $3.17  0.00% 
 Escalon Medical Corp. $1.19  0.00% 
 Essilor International $129.30  0.00% 
 Glaukos $26.26  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.36  0.00% 
 Inotek Pharmaceuticals $11.87  0.00% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $9.84  0.00% 
 Johnson & Johnson $102.37  0.00% 
 Luxottica Group, S.p.A. $66.20  0.00% 
 Merck & Company, Inc. $53.96  0.00% 
 NicOx $1.59  0.00% 
 NovaBay Pharmaceuticals, Inc. $0.16  0.00% 
 Novartis AG Common Stock $85.84  0.00% 
 Ocular Therapeutix $9.99  0.00% 
 Ophthotech Corporation $62.92  0.00% 
 QLT $2.81  0.00% 
 Quantel $2.93  0.00% 
 Regeneron $563.10  0.00% 
 Roche $33.49  0.00% 
 Second Sight Medical Products $4.98  0.00% 
 Shire $210.40  0.00% 
 STAAR Surgical Company $8.48  0.00% 
 TearLab Corporation $1.58  0.00% 
 Thrombogenics $4.35  0.00% 
 Topcon Corporation $14.05  0.00% 
 Valeant Pharmaceuticals $87.09  0.00% 
 Xoma $1.36  0.00%